Azurity’s Fleqsuvy Receives the US FDA’s Approval for the Treatment of Spasticity Associated with Multiple Sclerosis
Shots:
- The US FDA has approved Azurity’s Fleqsuvy (baclofen oral suspension) as a concentrated formulation for the treatment of spasticity related to MS or patients with spinal cord injuries and other spinal cord diseases
- The approval was based on a bioavailability study to evaluate baclofen (oral tablet) vs Fleqsuvy in healthy adults with the same indication. The results showed similar bioavailability of baclofen at 20mg dose level for the oral suspension and oral tablet formulations in the fasting conditions
- Fleqsuvy is supplied as a 25mg/5mL (5mg/mL) oral grape-flavored suspension and is available in bottles of 120mL or 300mL
Ref: PR Newswire | Image: Azurity
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
